Ocugen reports Q2 EPS (5c), consensus (6c)

Reports Q2 revenue $1.37M, consensus $350,000. “While our modifier gene therapy clinical trials advance-now with two in late-stage-we are securing strategic partnerships and evolving the business to support three successful Biologics License Application filings over the next three years,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen (OCGN). “We have also made important appointments to our Board of Directors, Retina Scientific Advisory Board, and Leadership Team to provide the Company with scientific and strategic know-how to bring us closer to delivering paradigm-changing gene therapies to millions of people with blindness diseases.”